ArticleThe oncologist2025
Impact of carboplatin schedule on pCR in a modified KEYNOTE-522 regimen with dose-dense AC for triple negative breast cancer.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs triple-negative breast cancer (TNBC) has a poorer prognosis when compared to hormone- and human epidermal growth factor 2-positive disease, it is vital to find treatments and schedules to improve outcomes inpatients with TNBC. The purpose of this study is to compare pathologic complete response (pCR) rates in early-stage TNBC between weekly versus every three-week carboplatin dosing with paclitaxel and pembrolizumab followed by dose-dense doxorubicin and cyclophosphamide (ddAC) and pembrolizumab in a modified KEYNOTE-522 regimen.
methodsA retrospective, single-center review was conducted on patients who received both treatment and surgery at the James Cancer Hospital at The Ohio State University Medical Center (The James) for TNBC with carboplatin, paclitaxel, and pembrolizumab followed by ddAC and pembrolizumab.
resultsA total of 92 patients were included in this study; 51 patients received weekly carboplatin and 41 patients received every three-week carboplatin. The pCR rate at time of surgery was 47.1% in the weekly group and 70.1% (P = 0.03) for the every three-week group. Dose reductions of chemotherapy (35.3% vs. 26.8%) and dose delays of greater than 7 days due to immunotherapy toxicities (23.5% vs. 14.6%) were greater in the weekly cohort. There were no differences in grade 3 or higher neutropenia between groups nor the use of granulocyte colony stimulating factor support. Infusion hypersensitivity reactions (iHSR) occurred in 19.6% of weekly patients and 4.9% of every three-week patients (P = 0.06).
conclusionIn this single-center analysis, every three-week carboplatin dosing followed by ddAC in a modified KEYNOTE-522 regimen provides higher pCR rates at the time of surgery. Patients who received weekly carboplatin dosing experienced more iHSR. These findings strongly warrant additional studies to determine the relationship of carboplatin dosing to TNBC outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.